19 July 2007
AstraZeneca expects to process $100 million (£50 million) of spend through its sourcing centre in China by 2010.
The pharmaceutical firm told SM it will begin sourcing and manufacturing most of its active pharmaceutical ingredients in China and India over the next five to 10 years.
The company established sourcing centres in Asia earlier this year and confirmed it intended to move production away from its current locations in Macclesfield in the UK and Plankstadt in Germany. The group currently has an annual purchasing spend of $9 billion (£4 billion).
Marc Jones, vice-president of external global sourcing, said the company would still have manufacturing capability in the medium term in Avlon, near Bristol, Dunkirk and Sweden, though this plant is being downsized.
"Our plans in China and India are embryonic but we see this as the way forward," he said.